1. Background
Over the past years, Acinetobacter baumannii has emerged as a serious nosocomial pathogen especially due to its extensively resistant antimicrobial profile. Colistin is currently used as one of the last resort agents to treat the related infections, but resistance due to monotherapy has increasingly been reported [1]. We evaluated the in vitro susceptibility of colistin-based antimicrobial combinations against extensively drug-resistant (XDR) A. baumannii isolates from a tertiary hospital in Northern Greece.
2. Materials
One hundred A. baumannii single clinical isolates with resistance to carbapenems and colistin between March and October 2021 were included in the study; 46 were isolated from blood, 41 from bronchoalveolar secretions, 6 from urine, 3 from central lines, 3 from skin and soft tissues, and 1 from cerebrospinal fluid. Antimicrobial susceptibility testing was performed by Vitek2 (bioMérieux, Lyon, France), whereas tigecycline, rifampicin, and daptomycin were tested with MIC test strip (Liofilchem, Italy), and colistin was tested with broth microdilution method (Liofilchem, Roseto degli Abruzzi, Italy). MIC range, MIC50, MIC90, and resistance rates were calculated according to EUCAST breakpoints. The MIC test strip fixed ratio method was used for the synergistic activity for three antimicrobial combinations of colistin with either meropenem, rifampicin, or daptomycin [2]. The results were interpreted using fractional inhibitory concentration index (FICI). ‘Synergy’, ‘additivity’, ‘indifference’, and ‘antagonism’ were interpreted when the FICI was ≤0.5, >0.5–≤1, >1–≤4, and >4, respectively [3].
3. Results
All the studied strains displayed high rates of resistance to major classes of antimicrobials (>97%) with 100% resistance to colistin (Table 1). MIC50/MIC90 (mg/L) for tigecycline were 3/6, for ampicillin/sulbactam 32/32, for rifampicin 6/32, and for daptomycin 256/256. All 100 isolates were tested for colistin/meropenem combination exhibiting 87% synergy (FICI range = 0.00078–0.5) and 13% additivity (FICI range = 0.56–0.84). Although rifampicin and daptomycin are typically inactive against Gram-negative bacteria, higher rates of synergy were observed using colistin/rifampicin combination with 93.75% (75/80) synergy (FICI range = 0.002–0.47), 3.75% (3/80) additivity (FICI range = 0.56–0.62), and 2.5% (2/80) indifference (FICI range = 1–1.42). Colistin/daptomycin combination was tested in 30 isolates, resulting in 90% (27/30) synergy (FICI range = 0.017–0.42) and 10% (3/30) additivity (FICI range = 0.51–0.76).
4. Conclusions
In vitro colistin-based combinations with either rifampicin or daptomycin or meropenem resulted in high synergy rates, rendering them a valuable option for the treatment of colistin-resistant A. baumannii infections.
Supplementary Materials
The presentation material can be downloaded at: https://www.mdpi.com/article/10.3390/eca2022-12735/s1.
Author Contributions
Conceptualization, P.M. and E.P.; methodology, P.M., A.K., M.A. and G.K.; software, G.M.; validation, P.M., E.P. and L.S.; investigation, G.M. and O.V.; resources, P.M. and L.S.; data curation, G.M. and G.K.; writing—original draft preparation, P.M., E.P., G.M.; writing—review and editing, E.P. and L.S.; visualization, P.M.; supervision, E.P. and L.S.; project administration, E.P.; funding acquisition, E.P. and L.S. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the AHEPA University.
Informed Consent Statement
Patient consent was waved due to the fact that all samples were obtained and tests were performed for diagnostics in terms of standard patient care.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Peleg, A.Y.; Seifert, H.; Paterson, D.L. Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 2008, 21, 538–582. [Google Scholar] [CrossRef] [PubMed]
- Laishram, S.; Pragasam, A.K.; Bakthavatchalam, Y.D.; Veeraraghavan, B. An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies. Indian J. Med. Microbiol. 2017, 35, 445–468. [Google Scholar] [CrossRef] [PubMed]
- Pillai, S.K.; Moellering, R.C.; Eliopoulos, G.M. Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005; pp. 365–435. [Google Scholar]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).